{"@id":"https://bioecon.ru/technology/mast-cell-targeted-therapeutics/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/mast-cell-targeted-therapeutics/","json":"https://en.bioecon.ru/api/v1/technology/mast-cell-targeted-therapeutics/index.json"},"id":"mast-cell-targeted-therapeutics","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/newlimit/","https://bioecon.ru/companies/altos-labs/","https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/cellmeat/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/simple-planet/","https://bioecon.ru/companies/integriculture/","https://bioecon.ru/companies/cryoport-systems/"]},"maturity":7,"name":"Mast-Cell Targeted Therapeutics","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Inhibitory receptor targeting"},{"n":2,"title":"Non-activating binding validation"},{"n":3,"title":"Apoptosis and degranulation assays"},{"n":4,"title":"Clinical efficacy in mast-driven pathology"}],"summary":"Precision biologics and receptor antagonists selectively engaging inhibitory surface receptors (e.g. Siglec-8, MRGPRX2, Kit/CD117) to inhibit degranulation or drive apoptosis of pathogenic tissue mast cells in severe allergic and mastocytosis disorders.","url":"/technology/mast-cell-targeted-therapeutics/","verified":"2026-11-22"}